Clinical Trials Logo

Adenocarcinoma of the Stomach clinical trials

View clinical trials related to Adenocarcinoma of the Stomach.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03722108 Terminated - Clinical trials for Adenocarcinoma of the Gastroesophageal Junction

Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

REGIRI
Start date: February 7, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Trial evaluating the efficacy of regorafenib combined with irinotecan compared to irinotecan alone in second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.

NCT ID: NCT01233505 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with capecitabine and oxaliplatin may kill more tumor cells.

NCT ID: NCT00871273 Terminated - Clinical trials for Adenocarcinoma of the Stomach

Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma

Start date: November 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (PK) of capecitabine in patients who have undergone a total gastrectomy.

NCT ID: NCT00098527 Terminated - Clinical trials for Recurrent Gastric Cancer

FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction. Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. FR901228 may also stop the growth of tumor cells by blocking some of the enzymes needed for their growth.